Therefore, we also suggest that even when patients could be classified as having PM/DM, the 2022 ACR/EULAR criteria for MPA should be applied to patients who have MPO-ANCA (or P-ANCA) and ILD as always as possible. The gene discussed is MPO; the disease is dermatomyositis.